Dr Paul Dai, PhD, co-founded and has served as Chairman and Chief Executive Officer of KAEDI since September 2016
As Chairman and CEO of KAEDI, Dr. Dai and his colleagues has successfully developed multiple efficient CAR-T pipelines for hematological malignancies and solid tumor therapy such as AML, liver cancer, brain cancer, pancreatic cancer and ovary cancer. Currently, KAEDI has successfully developed many kinds of R&D pipelines and three of them goes into clinical trial stage. Dr. Dai has published multiple high level papers in main cancer research journals and times cited more than 200. Dr. Dai and his team are pursuing advance progresses of KAEDI on next few years so that they could develop more first-in-class pipelines such as second generation, fourth generation and universal CAR-T products. 22 patents have been submitted, including 16 Chinese patents, 6 PCT international patents, 2 US patents and 8 pending patents. KAEDI has completed several cases of hematoma CART treatment, with excellent efficacy, without any fever and cytokine-induced toxic and side-effects. In addition, the ethics of clinical research on solid tumor KD-025 CART has been achieved and clinically accepted. Three cases were enrolled; KAEDI successfully completed 50 million preA and round A series of financing at the end of 2020, and expects to open B series of financing at the end of 2021.
Dr. Dai received his PhD from Shanghai institutes for biological sciences, CAS, in 2007 and then initiated his postdoctoral researches in UNL, UCR and UIC of US from 2008 to 2013. After that, he joined GS as senior scientist and then director of gene public division. Dr. Dai is cofounder of Nanjing KAEDI as Chairman and CEO from 2016. Dr. Dai has fantastic experiences in industrial synthetic biology and R&D operation. He joined the SC2.0 project, wherein the achievements have been published in Science.